Maurizio D'Incalci

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi request reprint Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, Milan, Italy
    Cancer Treat Rev 33:223-9. 2007
  2. ncbi request reprint Modulation of gene transcription by natural products--a viable anticancer strategy
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Curr Pharm Des 13:2744-50. 2007
  3. ncbi request reprint Unique features of the mode of action of ET-743
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Oncologist 7:210-6. 2002
  4. ncbi request reprint The combination of yondelis and cisplatin is synergistic against human tumor xenografts
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    Eur J Cancer 39:1920-6. 2003
  5. ncbi request reprint Preclinical and clinical results with the natural marine product ET-743
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Expert Opin Investig Drugs 12:1843-53. 2003
  6. ncbi request reprint New drugs from the sea
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, Milan, Italy
    J Chemother 16:86-9. 2004
  7. ncbi request reprint Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression
    Gianluca Tognon
    Department of Oncology, Flow Cytometry Unit, Mario Negri Institute, Milan, Italy
    Cancer Biol Ther 4:1325-30. 2005
  8. doi request reprint Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
    Michela Romano
    Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
    Int J Cancer 133:2024-33. 2013
  9. doi request reprint Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors
    Roberta Frapolli
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Clin Cancer Res 16:4958-67. 2010
  10. doi request reprint The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts
    Ezia Bello
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Mol Cancer Ther 12:131-40. 2013

Detail Information

Publications47

  1. ncbi request reprint Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, Milan, Italy
    Cancer Treat Rev 33:223-9. 2007
    ..Patients who are diagnosed with cancer want advice on how they may alter their diet or which diet supplements they should take to augment chemotherapy...
  2. ncbi request reprint Modulation of gene transcription by natural products--a viable anticancer strategy
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Curr Pharm Des 13:2744-50. 2007
    ....
  3. ncbi request reprint Unique features of the mode of action of ET-743
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Oncologist 7:210-6. 2002
    ....
  4. ncbi request reprint The combination of yondelis and cisplatin is synergistic against human tumor xenografts
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    Eur J Cancer 39:1920-6. 2003
    ..The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities. These results provide a rationale for testing the combination of Yondelis and DDP in the clinic...
  5. ncbi request reprint Preclinical and clinical results with the natural marine product ET-743
    Maurizio D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Expert Opin Investig Drugs 12:1843-53. 2003
    ..Further comparative studies are needed to define the role of ET-743 alone or in combination in cancer chemotherapy...
  6. ncbi request reprint New drugs from the sea
    M D'Incalci
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, Milan, Italy
    J Chemother 16:86-9. 2004
    ..Some of them appear to act by mechanisms different from those of conventional chemotherapeutic drugs and thus may be effective against tumors for which no active drugs are available...
  7. ncbi request reprint Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression
    Gianluca Tognon
    Department of Oncology, Flow Cytometry Unit, Mario Negri Institute, Milan, Italy
    Cancer Biol Ther 4:1325-30. 2005
    ..The finding that cells over-expressing Pgp are resistant to Aplidin was confirmed in CEM/VLB 100 cells, that was found to be 5-fold resistant to Aplidin compared to the CEM parental cell line...
  8. doi request reprint Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
    Michela Romano
    Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
    Int J Cancer 133:2024-33. 2013
    ....
  9. doi request reprint Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors
    Roberta Frapolli
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Clin Cancer Res 16:4958-67. 2010
    ..Recently the marine natural product trabectedin has shown highly selective activity for myxoid liposarcoma, even in the most aggressive round-cell subtype. Experimental..
  10. doi request reprint The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts
    Ezia Bello
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Mol Cancer Ther 12:131-40. 2013
    ..These data support the therapeutic potential of combining E-3810 with conventional chemotherapy...
  11. ncbi request reprint Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach
    Monica Lupi
    Biophysics Unit, Laboratory of Anticancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Cancer Res 64:2825-32. 2004
    ..We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations...
  12. ncbi request reprint Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity
    Matteo Simone
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, Milan, and Division of Pediatric Oncology, Catholic University A Gemelli, Rome, Italy
    Eur J Cancer 41:2366-77. 2005
    ..In conclusion, these variolins are a new class of CDK inhibitors that activate apoptosis in a p53-independent fashion and thus they may be effective against tumours with p53 mutations or deletions...
  13. doi request reprint Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
    Sergio Marchini
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy
    Eur J Cancer 49:520-30. 2013
    ..The present study is aimed to identify genetic pathways correlated with chemoresistance in epithelial ovarian cancer (EOC)...
  14. doi request reprint Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels
    Roberta Frapolli
    Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    Eur J Cancer 46:505-16. 2010
    ..To determine the pharmacokinetics of gimatecan, a camptothecin with a lipophilic substitution in position 7, given orally to patients participating in the phase I study...
  15. ncbi request reprint Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione
    Cristina Geroni
    Laboratory of Molecular Pharmacology, Department of Oncology, Mario Negri Institute of Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy
    Cancer Res 62:2332-6. 2002
    ..The decrease in brostallicin levels was monitored in these incubations; the rate of loss (and therefore brostallicin metabolism) was significantly higher for the M1-1 and P1-1 isoenzymes than for the A1-1 isoenzyme...
  16. doi request reprint Role of macrophage targeting in the antitumor activity of trabectedin
    Giovanni Germano
    Department Immunology and Inflammation, IRCCS Clinical and Research Institute Humanitas, 20089 Rozzano, Milan, Italy
    Cancer Cell 23:249-62. 2013
    ..This unexpected property may be exploited in different therapeutic strategies...
  17. ncbi request reprint The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer
    Sergio Marchini
    Department of Oncology, Mario Negri Gynecological Oncology Group, Milano, Italy
    Clin Cancer Res 18:4313-24. 2012
    ..We have now investigated the role of ZIC2 in driving tumor growth and its association with clinical outcomes...
  18. ncbi request reprint Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies
    Gianluca Tognon
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Cancer Chemother Pharmacol 53:89-90. 2004
  19. pmc A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma
    Sarah Uboldi
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    PLoS ONE 7:e35423. 2012
    ..The validation of these results in in vivo models might be clinically relevant to stratify myxoid liposarcoma patients with different sensitivity to trabectedin treatment...
  20. doi request reprint The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo
    Dario Brunelli
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Biochem Pharmacol 79:1141-8. 2010
    ..In vivo study showed that pure GMG-ITC was only slightly active in a carcinoma mice model, whereas it had significant antitumoral activity in a myeloma model, causing little toxicity...
  21. doi request reprint The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats
    Ilaria Cervellini
    Department of Molecular Biochemistry and Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Neurotox Res 18:151-60. 2010
    ..Since CINP induced by DOCE reproduces the clinical utility of taxane in humans, the findings reported might provide a basis for investigating EPO as a neuroprotective agent in patients receiving therapy with DOCE...
  22. doi request reprint Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
    Claudia Forni
    Dipartimento di Scienze Biomolecolari e Biotecnologie, Universita degli Studi di Milano, Milan, Italy
    Mol Cancer Ther 8:449-57. 2009
    ..These data provide a rationale for the specific activity of trabectedin and open the perspective of combinatorial treatments with drugs acting on lipogenic pathways...
  23. doi request reprint Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
    Federica Sala
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Mass Spectrom 46:1039-45. 2011
    ..The method has been successfully applied to study E-3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial...
  24. doi request reprint E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
    Ezia Bello
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, and E O S S p A, Milan, Italy
    Cancer Res 71:1396-405. 2011
    ..Taken together, our findings identify E-3810 as a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity, providing a strong rationale for its clinical evaluation...
  25. doi request reprint Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
    Federica Sala
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    J Mass Spectrom 45:1299-305. 2010
    ..The method was successfully applied to study the pharmacokinetics of CEP-18770 in cancer patients with solid tumors or multiple myeloma who had received the drug as a short intravenous bolus during the initial Phase I trial...
  26. doi request reprint A review of trabectedin (ET-743): a unique mechanism of action
    Maurizio D'Incalci
    Department of Oncology, Istiuto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Mol Cancer Ther 9:2157-63. 2010
    ..One of these combinations (trabectedin-pegylated liposomal doxorubicin) was recently authorized by the European Commission for the treatment of patients with relapsed platinum-sensitive ovarian cancer...
  27. doi request reprint Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study
    Federica Sala
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 877:3118-26. 2009
    ..Preliminary results show low and variable drug absorption in patients, with extensive glucuroconjugation influencing the bioavailability of ST1926...
  28. doi request reprint Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
    Giovanna Damia
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan 20157, Italy
    Eur J Cancer 45:2768-81. 2009
    ....
  29. doi request reprint Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts
    Massimo Zucchetti
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, Italy
    Cancer Chemother Pharmacol 66:635-41. 2010
    ..This study compared the antitumor activity and the pharmacological profile of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts...
  30. doi request reprint Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
    Massimo Zucchetti
    Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, 20156, Milan, Italy
    Cancer Chemother Pharmacol 72:879-87. 2013
    ..OTX008 is a galectin-1-targeting compound, currently undergoing a phase I clinical trial. This study aimed at investigating OTX008 pharmacokinetics (PK) and antineoplastic activity...
  31. doi request reprint Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities
    Paolo Ubezio
    Biophysics Unit, Laboratory of Anticancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Cancer Res 69:5234-40. 2009
    ..The results gained from this method provide a means for exploring new concepts regarding the drug-cell cycle interaction...
  32. doi request reprint Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells
    Valentina Colombo
    Laboratory of Anticancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    Cancer Chemother Pharmacol 67:369-79. 2011
    ..We studied whether silymarin pre-treatment synergized with chemotherapy, exploring the dose-dependence of the interaction in sensitive and multidrug-resistant cells...
  33. doi request reprint Trabectedin therapy for sarcomas
    Paolo G Casali
    Adult Sarcoma Medical Unit, Istituto Nazionale Tumori, Milan, Italy
    Curr Opin Oncol 22:342-6. 2010
    ..This was also due to increased consideration of their variegated histology. Trabectedin is a new chemotherapeutic agent, which significantly strengthens the armamentarium along this direction...
  34. doi request reprint Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers
    Roberta Sanfilippo
    Cancer Medicine Department, Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Gynecol Oncol 123:553-6. 2011
    ..The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma...
  35. ncbi request reprint Use of cancer chemopreventive phytochemicals as antineoplastic agents
    Maurizio D'Incalci
    Pharmacological Research Institute Mario Negri, Milan, Italy
    Lancet Oncol 6:899-904. 2005
    ..The restricted systemic availability of agents such as curcumin and epigallocatechin gallate, needs to be taken into account if they are to be developed as cochemotherapeutic drugs...
  36. ncbi request reprint Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance
    Massimo Rizzi
    Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy
    J Neurosci 22:5833-9. 2002
    ..P-gp alterations significantly affect antiepileptic drugs concentrations in the brain, suggesting that seizure-induced mdr mRNA expression contributes to MDR in epilepsy...
  37. doi request reprint Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections
    Sergio Marchini
    Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
    Lancet Oncol 12:273-85. 2011
    ..We profiled miRNA expression in stage I EOC tumours to assess whether there is a miRNA signature associated with overall and progression-free survival (PFS) in stage I EOC...
  38. doi request reprint Development and validation of a LC-MS/MS method for the determination of the novel oral 1,14 substituted taxane derivatives, IDN 5738 and IDN 5839, in mouse plasma and its application to the pharmacokinetic study
    Elena Marangon
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 877:4147-53. 2009
    ..0-113.3% and 85.9-105.7% for IDN 5738 and IDN 5839, respectively. With these methods, we studied for the first time, the pharmacokinetics of the two taxanes showing for both, good oral bioavailability (>50%)...
  39. ncbi request reprint Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production
    Paola Allavena
    Department of Immunology, Mario Negri Institute, Milan, Italy
    Cancer Res 65:2964-71. 2005
    ....
  40. doi request reprint Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors
    Lavinia Morosi
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology, Milano, Italy
    Curr Opin Pharmacol 13:807-12. 2013
    ..We overview here publications on MSI applied to studies of the distribution of anticancer agents in tumor tissue. In addition, we focused our attention on technical limitations and future perspectives pertaining to this technique. ..
  41. pmc The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma
    Marta Cesca
    Laboratory of Biology and Treatment of Metastases, Department of Oncology, Mario Negri Institute for Pharmacological Research, 20156 Milan, Italy
    Neoplasia 11:1155-64. 2009
    ..Analysis of vascular changes and PTX tumor uptake in vandetanib-treated tumors may help to guide the scheduling of vandetanib plus PTX combinations and may have implications for the design of clinical trials with these drugs...
  42. ncbi request reprint Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry
    Elena Marangon
    Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    J Mass Spectrom 43:216-23. 2008
    ..0 microg/ml (22.8 microM). The method was successfully used to study the drug pharmacokinetics in patients with advanced non-small-cell lung cancer in a phase II trial with gemcitabine administered as a fixed dose-rate infusion...
  43. doi request reprint Analysis of gene expression in early-stage ovarian cancer
    Sergio Marchini
    Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Clin Cancer Res 14:7850-60. 2008
    ..Gene expression profile was analyzed in 68 stage I and 15 borderline ovarian cancers to determine if different clinical features of stage I ovarian cancer such as histotype, grade, and survival are related to differential gene expression...
  44. pmc Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging
    Lavinia Morosi
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology, Milano, Italy
    PLoS ONE 8:e72532. 2013
    ..The protocol can be readily applied to investigate anticancer drug distribution in neoplastic lesions and to develop strategies to optimize and enhance drug penetration through different tumor tissues. ..
  45. ncbi request reprint Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection
    Nicola Celli
    Istituto di Ricerche Farmacologiche Mario Negri, G Paone Environmental Health Center, Consorzio Mario Negri Sud, Via Nacional, 66030 Santa Maria Imbaro, Chieti, Italy
    J Pharm Biomed Anal 34:619-30. 2004
    ..The method allowed demonstrating that APL is in a dynamic equilibrium between plasma and blood cells. Moreover, the method was successfully applied to the pharmacokinetic study of Aplidin in cancer patients...
  46. ncbi request reprint Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
    Federica Grosso
    Cancer Medicine Department, Adult Sarcoma Medical Treatment Unit, IRCCS Foundation National Cancer Institute, Milan, Italy
    Lancet Oncol 8:595-602. 2007
    ....
  47. ncbi request reprint Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth
    Roberto Bianchi
    Mario Negri Institute of Pharmacological Research, Milan, Italy
    Eur J Cancer 43:710-7. 2007
    ..0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment...